ArticleACR open rheumatology2026
An Exploratory Analysis of Antibody Dynamics in Isolated Organ Involvement of Antisynthetase Syndrome: A Single-Center Experience.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterize longitudinal anti-aminoacyl-tRNA synthetase (anti-ARS) antibody kinetics in antisynthetase syndrome (ASyS) with isolated organ involvement (IOI) and examine associations with clinical trajectories versus multiple organ involvement (MOI).
methodsWe retrospectively analyzed 23 patients with ASyS with serial anti-ARS antibody measurements (IOI, n = 12; MOI, n = 11). IOI was defined as involvement of a single organ domain, whereas MOI involved ≥2 domains. Anti-ARS antibody titers were measured using a five-antibody enzyme-linked immunosorbent assay panel. Cumulative antibody burden was quantified as area under the curve (AUC) normalized by observation time. Longitudinal trajectories were evaluated using a linear mixed-effects model.
resultsBaseline anti-ARS antibody titers were lower in IOI than MOI (median 84.1 [interquartile range (IQR) 57.6-117.5] vs median 163.0 [IQR 132.0-175.5]; P = 0.007). Among treated patients with longitudinal data (IOI, n = 7; MOI, n = 10), IOI exhibited a more consistent decline and lower cumulative exposure (normalized AUC: median 33.7 [IQR 32.5-61.7] vs median 103.0 [IQR 94.1-144.0]; P < 0.001). Population-level trajectories showed a steeper decline in IOI, with a significant group-time interaction (P = 0.026). In IOI, antibody reductions were concordant with KL-6 improvement and radiologic findings, and prednisolone tapering or discontinuation was achieved without relapse.
conclusionIOI was associated with lower baseline anti-ARS antibody titers and a more pronounced decline versus MOI. These findings support a stage-based framework in which IOI represents a phase with limited organ involvement. The integrated kinetic pattern-lower baseline titers, steeper decline, and lower cumulative exposure-may be associated with a more favorable treatment-associated clinical course.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.